Title
Evaluation of histomorphological changes in breast cancer following neoadjuvant therapy at a tertiary care centre, Jharkhand
Authors
Chanchal Ashok, Arvind kumar, Aditi Priya, Saurav Banerjee, Alimuddin Ansari & Sunil Mahto*
Affiliation
Department of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India; *Corresponding author
Chanchal Ashok - E-mail: chanchalashok239@gmail.com
Arvind Kumar - E-mail: drarvindk@rediffmail.com
Aditi Priya - E-mail: aditipriya11114@gamil.com
Saurav Banerjee - E-mail: dr_saurav2003@yahoo.co.in
Alimuddin Ansari - E-mail: alimansari3329@gmail.com
Sunil Mahto - E-mail: sooneel.mahto@gmail.com
Article Type
Research Article
Date
Received October 1, 2025; Revised October 31, 2025; Accepted October 31, 2025, Published October 31, 2025
Abstract
Breast cancer remains a major cause of cancer-related mortality among women worldwide, with treatment response prediction posing a persistent challenge. Neoadjuvant therapy (NAT) offers tumor downstaging and assessment of histopathological response. In this prospective study of 125 patients, NAT led to a significant reduction in tumor cellularity (82.4% ± 12.3% to 31.7% ± 18.9%, p < 0.001) and increased fibrosis (15.2% ± 8.7% to 48.6% ± 15.4%, p < 0.001). Pathological complete response (pCR) occurred in 32% of patients, with higher rates in triple-negative (42.1%) and HER2-positive (38.5%) subtypes. High post-NAT tumor-infiltrating lymphocytes correlated strongly with pCR (r = 0.67, p < 0.001). Thus, we show that NAT induces significant histomorphological changes, which can serve as key prognostic indicators for therapeutic response and patient outcomes.
Keywords
Breast cancer, histological, changes, therapy
Citation
Ashok et al. Bioinformation 21(10): 3770-3774 (2025)
Edited by
Hiroj Bagde
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
